Shahab Najafi
About Shahab Najafi
Shahab Najafi is a Senior Manager in Downstream Manufacturing and Fill Finish at Tenaya Therapeutics, with extensive experience in the biotechnology sector, including roles at BioMarin Pharmaceutical Inc. and Audentes Therapeutics.
Current Position at Tenaya Therapeutics
Shahab Najafi serves as the Senior Manager for Downstream Manufacturing and Fill Finish at Tenaya Therapeutics. He has held this position since 2021, contributing to the company's efforts in the biopharmaceutical sector. His role involves overseeing manufacturing processes and ensuring compliance with industry standards.
Previous Experience in Biopharmaceuticals
Prior to his current role, Najafi accumulated extensive experience in the biopharmaceutical industry. He worked at BioMarin Pharmaceutical Inc. in various capacities, including Technician in Clinical Manufacturing, Tech Transfer Specialist II, Manufacturing Process Implementation Senior Specialist, and Manager of Learning Application. His tenure at BioMarin spanned from 2007 to 2018, providing him with a solid foundation in clinical manufacturing and process implementation.
Experience at Audentes Therapeutics
Najafi held multiple positions at Audentes Therapeutics, where he served as Supervisor and later as Senior Supervisor from 2018 to 2021. His responsibilities included managing teams and overseeing manufacturing operations related to gene therapy. This experience enhanced his leadership skills and knowledge in the field.
Education and Academic Background
Shahab Najafi completed his Bachelor’s degree in Molecular and Cell Biology at the University of California, Berkeley, from 2002 to 2006. He also attended Orange Glen High School. His educational background provides a strong foundation for his career in the biopharmaceutical industry.
Short Tenure at Ology Bioservices, Inc.
In 2021, Najafi worked for a brief period as Manager of Cell and Gene Therapy Manufacturing at Ology Bioservices, Inc. His role lasted for five months, further diversifying his experience in the biopharmaceutical manufacturing landscape.